{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Others > Astragaloside ⅣCAS：84687-43-4
Molecular Formula：C41H68O14
Molecular Weight：784.98
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 84687-43-4 |
| Name | Astragaloside Ⅳ |
| Molecular Formula | C41H68O14 |
| Molecular Weight | 784.98 |
| Solubility | Soluble in DMSO ≥10mg/mL |
| Purity | HPLC≥98% |
| Appearance | White to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 1532714-185-1 |
| MDL | MFCD16036240 |
| SMILES | O[C@H]1[C@H](O)[C@@H](O)[C@]([H])(O[C@@H]2C(C)(C)[C@@]([C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C[C@]4([H])[C@@]56CC[C@@]7(C)[C@@]4(C)C[C@H](O)[C@]7([H])[C@]8(C)O[C@H](C(C)(O)C)CC8)([H])[C@]5(C6)CC2)OC1 |
| InChIKey | QMNWISYXSJWHRY-YLNUDOOFSA-N |
| InChI | InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1 |
| PubChem CID | 13943297 |
| Target Point | ERK;JNK |
| Passage | MAPK |
| Background | It is a biologically active saponin that can be used for research in cardiovascular, immune, digestive and nervous systems. Can inhibit the activation of ERK1/2 and JNK. |
| Biological Activity | Astragaloside IV 是从黄芪中分到的皂苷类物质，能够抑制 ERK1/2 和 JNK 的激活，在乳腺癌细胞 MDA-MB-231 中，能够下调 (MMP)-2，(MMP)-9 的信号通路。[1-4] |
| Data Literature Source | [1]. Li M，et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. Neurosci Lett. 2016 Dec 20. pii: S0304-3940(16)30994-6 [2]. He CS，et al. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221-1229. Epub 2016 Dec 14. [3]. Liu L，et al. [Protective effect of astragaloside IV against acute liver failure in experimental mice]. Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):772-777. [4]. Jiang K，et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2016 Dec 5;42:195-202 |
| Unit | Bottle |
| Specification | 20mg 10mM*1mL in DMSO 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Li JJ, et al. Phytomedicine. 2023 Jan;109154605.
Li JJ, et al. Phytomedicine. 2023 Jan;109154605.
Sorry, there is no more information.
Astragaloside IV alleviates cytarabine-induced intestinal mucositis by remodeling macrophage polarization through AKT signaling
Click to check >>Author：Li JJ. Li YL. Chu W. Li GQ. Zhang M. Dong JJ. Li L
IF：5.0370
Publish_to：Phytomedicine
PMID：36610133
Astragaloside IV inhibits cell invasion and metastasis in vulvar squamous cell carcinoma through the TGF-β1/FAK/AKT signaling pathway
Click to check >>Author：Zhao Y Y . Zhang H Y
IF：1.0690
Publish_to：Ginekologia Polska
PMID：
Manual Download
